Rheumatoid arthritis (RA) is an autoimmune disease that causes joint inflammation and destruction.1 There is currently no cure – and although there are many treatments, their effectiveness varies from person to person, suggesting an undefined pathogenic diversity.1 Deep characterisation of myeloid cell subsets by single cell RNA sequencing across healthy and inflamed tissues in RA has led to the identification of new pathogenic cell states and subsets – with data coming from five large-scale studies.1-5 But subset overlap across studies and compartments – such as in blood versus synovial tissue – has not yet been systematically investigated.
Presenting at the 2024 EULAR congress in Vienna, Sebastien Viatte explained “we wanted to map monocyte subsets and states across studies and compartments to identify blood monocyte precursors of inflammatory synovial macrophage subsets observed in people with RA.”
With this in mind, the group set out to discover whether quiescent human blood monocyte states are pre-committed to an inflammatory synovial transcriptional program. First, peripheral blood mononuclear cells (PBMC) from healthy volunteers and RA patients with clinically well-controlled disease (quiescent PBMC) were enriched for monocytes by negative selection and subjected to single cell RNA sequencing. The researcher then used published myeloid cell subsets to map on to their template, based on the similarity of their expression scores. Hierarchical methods were applied to merge similar clusters and create a consensus map, and random forests were used to merge over-clustered data and identify novel myeloid cell states – and generate a final taxonomy of monocyte states in healthy human blood. Finally, to provide experimental validation at the protein level, PBMC from 19 RA patients with uncontrolled inflammation were deeply immunophenotyped, and inflammatory cell states with increased abundance in RA were identified.
All told, this work generated an exhaustive reference atlas comprising a total of 11 monocyte states across anatomical compartments relevant for RA. For example, it was possible to show that different clusters in fact represent the same inflammatory synovial macrophage subset, and are transcriptionally similar to an IL1B+ monocyte subset present in quiescent peripheral blood.
The findings also revealed that four quiescent monocyte states present in the peripheral blood of both RA patients and healthy individuals expand in the blood of patients with uncontrolled RA. These likely represent blood precursors of pathogenic tissue macrophages.
This work is important, because it not only defines a new monocyte cell taxonomy relevant for RA – with 11 continuous cell states that dynamically transition into each other across anatomical compartments – but also identifies potential blood precursors of pathogenic tissue macrophages.
Source
Amies E, et al. Quiescent human blood monocyte states are pre-committed to an inflammatory synovial transcriptional program. Presented at EULAR 2024; OP0111.
Ann Rheum Dis 2024; DOI: 10.1136/annrheumdis-2024-eular.5134.
References
1. Zhang F, et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature 2023;623(7987):616–24.
2. Villani A-C, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 2017;356(6335):eaah4573.
3. Kuo D, et al. HBEGF+ macrophages in rheumatoid arthritis induce fibroblast invasiveness. Sci Transl Med 2019;11(491):eaau8587.
4. Alivernini S, et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat Med 2020;26(8):1295–306.
5. Zhang F, et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol 2019;20(7):928–42.
About EULAR
EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.
Contact
EULAR Communications, communications@eular.org
Notes to Editors